Browse the evidence

In trials without SGLT2 inhibitors, there was a significant reduction of 21% in new-onset AF.

Semaglutide may be more effective in reducing AF risk when not used with SGLT2 inhibitors.

Moderate coffee consumption is not associated with increased risk of CVD.

Health professionals can reassure patients that moderate coffee intake is safe regarding CVD risk.

Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.

Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.

Semaglutide improved physical quality of life by 3.75 points on the SF-36v2.

Semaglutide may enhance physical quality of life for patients in this group.

GLP-1RA users had a lower risk of stroke (HR, 0.81; 95% CI, 0.70-0.93) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing stroke risk in this population.

GLP-1RA users had a lower risk of all-cause mortality (HR, 0.70; 95% CI, 0.63-0.78) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing all-cause mortality in this population.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

The consensus defines sarcopenic obesity with a 3-step algorithm, including screening, diagnosis, and intervention.

Practitioners can use this algorithm for diagnosing and managing sarcopenic obesity.

Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.

Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.

Visceral obesity is correlated with cardiometabolic diseases and higher mortality.

Monitoring visceral fat levels can be crucial for assessing mortality risk.

Physical activity and exercise training modify the biological effects of accelerated aging considerably.

Incorporating regular physical activity and exercise can significantly mitigate the effects of aging on cardiovascular health.

GLP-1 receptor agonists and co-agonists were associated with a lower risk of incident atrial fibrillation among individuals with overweight or obesity.

Practitioners may consider GLP-1RAs and co-agonists as potential options for reducing atrial fibrillation risk in overweight or obese patients.

Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).

Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.

Tirzepatide was more efficacious in younger, male patients of White ethnicity.

Treatment strategies may need to be tailored based on demographic factors for optimal outcomes.

Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).

Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.

Incretin-based therapies were associated with a mean reduction in the apnea-hypopnea index (AHI) of -14.45 events/h.

Incretin-based therapies may effectively reduce AHI in OSA patients, improving sleep quality.

Incretin-based therapies showed a greater effect on AHI compared to usual care, with a mean difference of -11.61 events/h.

Incretin-based therapies may be more effective than usual care for improving AHI in OSA patients.

Individuals with obesity are at greater risk for developing metabolic diseases such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and cardiovascular diseases.

Healthcare providers should monitor metabolic health in patients with obesity.

GLP-1RA use in MUHO is associated with a lower risk of ischemic stroke (HR 0.921) compared to non-use.

GLP-1RAs may be beneficial for reducing ischemic stroke risk in MUHO patients.

Patients with metabolically healthy obesity (MHO) have a markedly lower risk of clinical events compared to those with metabolically unhealthy obesity (MUHO).

Understanding the risk differences can guide treatment decisions for obesity management.

Most ultraprocessed foods overlap with foods high in saturated fat, added sugars, and sodium.

Practitioners should consider the nutritional content of UPFs when advising clients.

Tirzepatide achieved similar 12-month TBWL% as R-ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04).

Tirzepatide may be a viable alternative for weight loss in patients post-sleeve gastrectomy, potentially outperforming semaglutide.

Discontinuation rates were strongly associated with copayment amount, increasing from 41% in the lowest quintile to 51% in the highest quintile.

Financial considerations significantly impact patient adherence to semaglutide treatment.